BEW EnggQ1 FY25
BEW Engg
Q1 FY25 Earnings Call Analysis
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Targeting revenue of around Rs. 175 crores for FY '26, with confidence due to a strong current order book of Rs. 80 crores and positive CAPEX trends in Pharma, Agro Chemicals, and Specialty Chemicals sectors.
- →Expect gradual growth in EBITDA margins from current levels (~15%) towards 20%-22% by FY '27, contingent on stable market conditions.
- →Capacity expansion nearly doubling production capacity, enabling the company to target Rs. 300 crores revenue in 2-3 years without adding new capacity.
- →Strong focus on building order book, especially from Pharma and Agro Chemicals, which are anticipated to be key growth drivers.
- →New orders from reputed pharma customers and market traction seen over past 2 months.
- →Strategic efforts on export growth, especially in Africa, Japan, Middle East, South Africa, Israel, and Russia.
- →Operational efficiencies and inventory cycle normalization expected to support growth and margin improvements.
Margin guidance
Category 3- →Revenue target is around Rs. 175 crore for FY '26, with a potential to reach Rs. 300 crore by FY '27 due to expanded capacity.
- →EBITDA margin expected to gradually grow from 15% in FY '26, aiming for 20%-22% in FY '27 if market conditions remain stable.
- →Profit after tax showed a decrease in FY '25 but is expected to improve with better order flow and operational efficiencies.
- →The company anticipates strong order inflows particularly from Pharma and Agro Chemical sectors, supporting growth.
- →Earnings per share (EPS) decreased from Rs. 46.56 in FY '24 to Rs. 9.30 in FY '25 but with revenue growth and margin expansion, EPS is expected to improve.
- →Inventory and working capital normalization strategies are in place to enhance margins and cash flow going forward.
Sign up free to read the full earnings analysis
Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for BEW Engg and 1,400+ other companies.
Fundraise plans
- →There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
- →However, the company is targeting a 20% reduction in debt to enhance balance sheet strength and cash flow visibility.
- →There is no discussion about raising new equity or taking on new debt for expansion or operational needs in the current or upcoming fiscal years.
- →The focus appears to be on operational efficiency, capacity expansion, and improving working capital cycles rather than raising fresh capital.
Order book
Yes- →Current order book stands at around Rs. 80 crores as of end of the last reported period (March 31, 2025).
- →Recent months have seen good traction in orders, especially from the Pharma and Agro Chemicals sectors.
- →The company is witnessing increased order inflows and expects the order book to grow due to ongoing CAPEX activities at customer end.
- →With expanded manufacturing capacity nearing completion, the company is confident in taking and delivering more orders promptly.
- →The management is optimistic about steady order flow ahead, particularly from Pharma, Agro, and Specialty Chemicals sectors.
- →Target revenue for FY '26 is Rs. 175 crores, indicating confidence in order conversion and additions.
- →For the next 2-3 years, the company aims to reach Rs. 300 crores in revenue leveraging current capacities.
Capex plans
Yes- →BEW Engineering has recently completed an expansion of its manufacturing facility.
- →The expansion was driven by current capacity utilization at around 90%, requiring more space for manufacturing and raw material storage.
- →The additional capacity is expected to enable revenue growth potential up to Rs. 300 crores over the next 2-3 years without the need for further capacity addition.
- →Management is confident in timely delivering orders due to the expanded facility nearing completion.
- →Going forward, the company sees good traction and CAPEX ordering from key sectors like Pharmaceuticals and Agro Chemicals.
- →There is no specific mention of fresh strategic investments or new capital expenditure projects in the immediate future beyond the recently completed expansion.
- →The focus is on leveraging the expanded capacity and operational efficiencies for growth and improving working capital cycles.
How does BEW Engg rank vs peers in Industrial Manufacturing?
Pro feature1BEW Engg
Rev 3Mar 3
See full Industrial Manufacturing sector rankings
Unlock with ProWant more stocks like BEW Engg?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio